Sarah Gaffey

Foundation Medicine (United States)

Medicine · Health Sciences

19h-index2.8kcitations67works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(55), Cancer Immunotherapy and Biomarkers(23), Cancer Genomics and Diagnostics(10), Brain Metastases and Treatment(10), Immune cells in cancer(9)

Publications67 total

Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform
Contemporary Clinical Trials Communications·2025· 1 citedOpen Access
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
Journal of Clinical Oncology·2023· 42 cited
Table 1 from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Figure from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
2023Open Access
Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Figure from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
2023Open Access
Supplementary Data from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
2023Open Access
Supplementary Figure from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
2023Open Access
Supplementary Materials from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
2023Open Access
Data from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
2023Open Access
Supplementary Figure from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
2023Open Access
Data from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
2023Open Access
Supplementary Figure from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
2023Open Access
Supplementary Table 2 from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Data from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
2023Open Access
Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Table 2 from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Figure from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
2023Open Access
Supplementary Materials from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
2023Open Access
Table 1 from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Patrick Y. Wen(45), David A. Reardon(44), Lakshmi Nayak(33), Eudocia Q. Lee(32), Alona Muzikansky(25), Christine McCluskey(24), Andrew D. Norden(19), Lisa Doherty(19), Thomas Kaley(18), Howard Colman(17), Rameen Beroukhim(16), Katrina H. Smith(16), Mikael L. Rinne(15), Keith L. Ligon(15), David Schiff(15), Jennifer Clarke(14), Jan Drappatz(14), Brian M. Alexander(13), Tracy T. Batchelor(12), Debra C. LaFrankie(12)